Literature DB >> 10233897

Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia.

B Hugel1, G Socié, T Vu, F Toti, E Gluckman, J M Freyssinet, M L Scrobohaci.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH), frequently occurring during suppressed hematopoiesis including aplastic anemia (AA), is a clonal disorder associated with an increased incidence of thrombotic events. Complement-mediated hemolysis, impairment of the fibrinolytic system, or platelet activation are thought to be responsible for the associated thrombotic risk. We investigated here the elevation of membrane-derived procoagulant microparticles in the blood flow of such patients. Elevated levels of circulating microparticles were in fact detected in both de novo PNH patients and AA subjects with a PNH clone, but not in those with AA without a PNH clone. The cellular origin of the microparticles was determined in PNH samples; most stemmed from platelets. Glycophorin A+ particles were rarely detected. Therefore, platelet activation, resulting in the dissemination of procoagulant phospholipids in the blood flow, could be one of the main causes for the elevated thrombotic risk associated with PNH. These observations suggest that shed membrane particles can be considered a valuable biological parameter for the assessment of possible thrombotic complications in patients with PNH.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233897

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Isolated central retinal artery occlusion as an initial presentation of paroxysmal nocturnal hemoglobinuria and successful long-term prevention of systemic thrombosis with eculizumab.

Authors:  Hyun Seung Yang; So Hyun Park; Jung Ran Choi; June-Gone Kim
Journal:  Jpn J Ophthalmol       Date:  2013-06-14       Impact factor: 2.447

2.  Red blood cell microparticles: clinical relevance.

Authors:  Olivier Rubin; Giorgia Canellini; Julien Delobel; Niels Lion; Jean-Daniel Tissot
Journal:  Transfus Med Hemother       Date:  2012-08-27       Impact factor: 3.747

Review 3.  Hypercoagulability and thrombotic complications in hemolytic anemias.

Authors:  Kenneth I Ataga
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

Review 4.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

5.  Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Authors:  Elaine M Sloand; Loretta Pfannes; Phillip Scheinberg; Kenneth More; Colin O Wu; McDonald Horne; Neal S Young
Journal:  Exp Hematol       Date:  2008-10-26       Impact factor: 3.084

6.  Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Authors:  Dominique Helley; Régis Peffault de Latour; Raphaël Porcher; Celso Arrais Rodrigues; Isabelle Galy-Fauroux; Jeanne Matheron; Arnaud Duval; Jean-François Schved; Anne-Marie Fischer; Gérard Socié
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

7.  Biologic nanoparticles and platelet reactivity.

Authors:  Virginia M Miller; Larry W Hunter; Kevin Chu; Vivasvat Kaul; Phillip D Squillace; John C Lieske; Muthuvel Jayachandran
Journal:  Nanomedicine (Lond)       Date:  2009-10       Impact factor: 5.307

8.  Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents.

Authors:  Antonio M Risitano; Bruno Rotoli
Journal:  Biologics       Date:  2008-06

Review 9.  Thrombin inhibitors from different animals.

Authors:  A M Tanaka-Azevedo; K Morais-Zani; R J S Torquato; A S Tanaka
Journal:  J Biomed Biotechnol       Date:  2010-10-04

10.  The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.

Authors:  Richard Kelly; Stephen Richards; Peter Hillmen; Anita Hill
Journal:  Ther Clin Risk Manag       Date:  2009       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.